To read the full story, subscribe or sign in.

Clear Creek Bio starts phase I study of brequinar for treatment of COVID-19

Sep. 4, 2020

No Comments

BioWorld Science Infection

Today's news in brief

BioWorld

BioWorld briefs for Nov. 30, 2023.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for November, 30 2023.

Aurinia Therapeutics’ AUR-300 proven useful in systemic sclerosis

BioWorld Science

Aurinia Pharmaceuticals Inc. has investigated their CD206 ligand AUR-300 as a novel therapeutic agent for systemic sclerosis treatment.

‘Ridiculous’ site-based hitches mar Biovie phase III in Alzheimer’s

BioWorld

For the second time this week, a contract research organization has come under fire for trial-conduct issues – criticism leveled most recently by Biovie Inc.,...

Astrazeneca’s AKT inhibitor is approved in breast cancer

BioWorld

Along with Enhertu, Astrazeneca plc now has another breast cancer treatment in its portfolio and it may also become a blockbuster. Truqap (capivasertib), combined...

Upgrade your daily dose of biopharma and medtech news

Clear Creek Bio starts phase I study of brequinar for treatment of COVID-19